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Cervical cancer incidence rates in South Africa 
(SA) have reached epidemic proportions, where 
cervical cancer accounts for 18.0/100  000 of deaths 
(age-standardised rate). Cancer of the cervix is the 
leading cause of cancer-related death in Africa.[1] 
HIV infection increases the risk of developing cervical cancer and 
lowers the age at diagnosis.[2]
Although the disease is largely preventable through screening 
programmes aimed at treatment of detected cancer precursor lesions, 
successful screening programmes have not been implemented 
anywhere in the developing world.[3] Fortunately effective vaccines 
are registered and available against the viral cause of the disease, 
namely human papillomavirus (HPV).[4] Before 2014, these vaccines 
were not yet introduced into the national vaccine programme in 
SA – the Expanded Program on Immunization (EPI). During 2014, a 
two-dose vaccination programme was introduced in some schools for 
girls in grade 4 in SA. The vaccines are available for private healthcare 
users, but are underutilised in this sector as well. It is predicted that 
in the future cervical cancer vaccination will be a more cost-effective 
and much more effective strategy than screening for this disease.[5]
HPV vaccines were originally tested in a three-dose regimen in 
adult women and found to be highly immunogenic and effective 
in preventing cervical cancer precursor lesions. Recently new data 
have demonstrated that vaccination with two doses of the same 
vaccine in younger girls (aged 9 - 14 years) also provides high levels 
of antibodies. Indeed, the antibody response was demonstrated to 
be non-inferior to the immunogenicity obtained with a two-dose 
schedule in females aged 15 - 25 years. A similar safety profile was 
also demonstrated when compared with the three-dose group.[6,7]
Countries in the developed and developing world are increasingly 
opting to provide two doses of HPV vaccine as part of their national 
policy in response to these preliminary data. This method of bridging 
to efficacy data is a well-established approach in vaccinology. It 
is proposed that introduction of the HPV vaccine into the EPI 
programme in SA will be greatly facilitated by providing only two doses 
(at months 0 and 6) to primary school girls, while immunogenicity will 
be uncompromised because of the young age of the recipients.[7] Herd 
immunity will depend upon high uptake and completion rates, while 
affordability and success of the programme will also depend upon 
resources needed as well as direct and indirect programme costs.
The first arm of the Vaccine and Cervical Cancer Screen (VACCS) 
project (VACCS 1) showed that cervical cancer screening of women 
with self-testing can be successfully linked to implementation of 
an HPV vaccination programme at the schools attended by their 
daughters. In this trial, the conventional three-dose regimen was used 
and more than 1 000 girls were vaccinated.[8]
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Background. Cervical cancer is a preventable disease with a high prevalence in South Africa (SA), where screening is opportunistic. 
Primary prevention is now possible through HPV vaccination. In VACCS 1 the feasibility of linking cervical cancer with HPV vaccination 
was demonstrated.
Objectives. To investigate the feasibility of linking HPV self-testing with a two-dose HPV vaccination schedule and to compare results with 
VACCS 1.
Methods. The project was conducted in five schools in the South-West District of Tshwane, Gauteng, SA. Leaflet information on cervical 
cancer and screening was provided, with requests for consent and assent for a two-dose HPV vaccination of schoolgirls. Female caregivers 
were invited to take part in HPV self-screening.
Results. Of 965 girls invited for vaccination, 519 (53.7%) had full consent and 518 (99.8%) received at least one vaccine dose. The invited 
uptake rate was 53.7% and 495 girls received both doses, giving a completion rate of 95.4% v. 82.6% in VACCS 1. Of 1 135 self-screen kits 
handed out, 560 (49.3%) were not returned. The mean age (standard deviation) of the 160 women who participated in self-screening was 
38.7 (7.7) years. HPV testing was negative in 116 women (72.5%), 15 women (9.4%) tested positive for HPV 16 and/or 18, and 27 (16.9%) 
were positive for non-16/18 oncogenic HPV.
Conclusion. Data from the VACCS projects suggest that school-based vaccine programmes can be successfully implemented. A two-dose 
schedule allowed for higher completion rates. Linking self-collected HPV screening to HPV vaccination is feasible, is a promising and viable 
screening strategy, and reached the appropriate age group for screening.
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The current study, done in the same district as VACCS 1, aimed to 
investigate the feasibility of linking two-dose vaccination of eligible 
primary school girls with HPV self-testing of their female caregivers. 
In addition, this study compared some differences in methodology 
and outcomes with the first VACCS project. Screening uptake and 
outcomes were also investigated and compared with the outcomes 
achieved in VACCS 1. The major differences in study methods 
between VACCS 1 and 2 included the invitation to female parents 
and guardians to take part in self-screening, the two-dose vaccination 
schedule, and the collection and testing of HPV DNA. HPV tests 
were sent with the girls attending school and, unlike with VACCS 1, 
there were no additional information events in the form of an oral 
presentation presented by a doctor.
Methods
As with the first VACCS project, this national study was conducted in 
Gauteng and Western Cape provinces with the approval of the national 
and provincial departments of Basic Education and Health. The 
method and results of the Gauteng part of the study are described here.
Five primary schools neighbouring those in which girls had been 
vaccinated in VACCS 1 were identified in the South-West District of 
Tshwane. After obtaining consent from the governing body and princi-
pal of each school, study packs containing printed leaflet information, 
informed consent and assent forms and self-screen kits were handed out 
to all the girls in grades 4 - 7 (aged ≥9 years) to take home.
The printed leaflet contained information about cervical cancer 
and its symptoms, accurate and complete information about the 
safety and efficacy of the HPV vaccine for primary prevention 
of cervical cancer, and information on screening for the disease. 
Parents and guardians of eligible girls were requested to provide 
informed consent for a two-dose HPV vaccine schedule, while all 
eligible girls were requested to provide assent for vaccination. Two 
bivalent vaccine doses donated by the manufacturing company were 
administered to the consented girls, 6 months apart, by a team of 
registered nurses during school hours.
Female parents and guardians of eligible girls were invited to take 
part in self-administered HPV screening. The screen kit consisted of 
a sample collector with user instructions available as an Evalyn brush. 
Specimens together with personal information were returned to the 
school in sealed containers. DNA was extracted from the Evalyn 
brush and tested using Roche Cobas 4800.[9] HPV DNA results 
were reported as positive for HPV 16, HPV 18 and other high-risk 
HPV (hrHPV) types (31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68) or 
negative for oncogenic HPV.
HPV test results were interpreted as positive if DNA of any of the 
15 high-risk viral types was found, and were interpreted as invalid 
if no DNA amplification occurred as tested by the internal control.
Women who screened positive were informed of the results via the 
school system and by making use of mobile phone technology, and invited 
to the gynaecology department at Kalafong Hospital for treatment or 
requested to visit their own healthcare provider with the screen results.
Definitions
The invited cohort (IC) was defined as all female learners enrolled in 
the selected schools in grades 4 - 7 and the consented cohort (CC) as 
participants with written consent from the parent or guardian as well 
as assent from the learner. Girls whose parents or guardians had given 
consent but who did not attend vaccine events were included in the CC. 
The vaccinated cohort (VC) comprised all girls who received at least 
one vaccine dose. Vaccine uptake rates were calculated in a number of 
ways in order to allow comparison with other published HPV vaccine 
reports and with VACCS 1. The consented uptake rate (CUR) was 
calculated as VC/CC and the invited uptake rate (IUR) as VC/IC.
Vaccine completion rates (VCRs) were determined using the vaccine 
cohort as a denominator. The VCR was calculated using all girls who 
received both vaccine doses, while the insufficiently vaccinated rate 
(IVR) used the number of girls who received only one vaccine dose.
The study was approved by the Research Ethics Review Committee 
of the Faculty of Health Sciences, University of Pretoria (90/2013).
Results
Vaccination data
In the five schools selected for the project, the IC consisted of 965 
girls. The CC consisted of 519 girls (53.7%) of whom 518 received 
the first vaccine dose (VC), giving a consented uptake rate of 99.8%. 
The IUR was 53.7%. Four hundred and ninety-five girls received both 
doses and 23 received only one dose, resulting in an IVR of 4.4%. The 
VCR was 95.4% for two doses.
The vaccination uptake and completion rates for the five different 
schools are shown in Table 1. One adverse event was reported as 
a rash developing a few hours after vaccination in a girl known to 
be allergic to various substances, but could not be confirmed to be 
related to the vaccine.
Screening
A total of 1 135 self-screen kits were handed out to eligible girls 
attending the five schools, to be passed on to their female parents and 
guardians. Female staff members at the schools also requested self-
screen kits, which accounts for the difference between the numbers of 
tests handed out and the IC. Of the 1 135 self-screen kits handed out, 
378 (33.3%) were returned unused and undamaged, 37 (3.3%) were 
unused but damaged, and 560 (49.3%) were not returned. Unused but 
damaged kits were not tested for the presence of HPV DNA.
One hundred and sixty women participated in self-screening. The 
return rate as a proportion of tests distributed was 14.1%. Screening 
uptake was 16.6% when calculated as a proportion of the IC (160 from 
965) and 30.8% when calculated as a proportion of the CC (160 from 
519). The proportion of the CC was calculated to compare with similar 
Table 1. Vaccination uptake and completion rates for the different schools
School IC, n CC, n VC, n IUR, % CUR, % Received 2 doses, n VCR, % Received 1 dose, n IVR, %
1 351 156 156 44.4 100.0 149 95.5 7 4.5
2 203 136 135 66.5 99.3 128 94.1 7 5.2
3 226 120 120 53.1 100.0 113 94.2 7 5.8
4 25 16 16 64.0 100.0 16 100.0 0 0.0
5 160 91 91 56.8 100.0 89 97.8 2 2.2
Total 965 519 518 53.7 99.8 495 95.4 23 4.4
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uptake rates calculated in VACCS 1.[8] A 
comparison of the different screen uptake 
rates is presented in Table 2.
When calculating screening uptake, the 
size of the true target population needs to 
be clarified. Although not investigated in the 
current study, data from the questionnaires 
administered to a similar population during 
the VACCS 1 study suggested that at least 
52.6% of women were in need of a screening 
test (‘had last test >10 years ago’). Using 
these data, the true target population in 
VACCS 2 is 538 women, corresponding to 
an uptake of 29.7%.
The mean (standard deviation) age of 
women participating in self-screening was 
38.7 (7.7) years (range 20 - 67). The age distri-
bution for this population is shown in Fig. 1.
Of the 160 women tested, 2 (1.3%) 
had invalid tests and 116 (72.5%) tested 
negative for hrHPV. Fifteen women (9.4%) 
tested positive for HPV 16 and/or 18 and 
27 (16.9%) tested positive for non-16/18 
hrHPV (Fig. 2). Of the 15 women who tested 
positive for HPV 16/18, 3 had only HPV 
16 and 1 had only HPV 18. Eleven women 
tested positive for both HPV 16 and 18. 
These screening results per age group are 
shown in Fig. 2. The comparative data from 
VACCS 1 are shown in Table 3.
Discussion
Reported vaccine uptake differs widely and 
is influenced by many factors such as social, 
religious, cultural and awareness aspects.[10] 
School-based vaccination programmes also 
tend to be more effective than other pro-
grammes.[11] In this study, informed consent 
from parents as well as assent from the girls 
were prerequisites for inclusion in the vaccine 
cohort. A vaccine uptake rate of 53.7%, 
calculated as a proportion of all girls eligible for 
vaccination, compares well with reports from 
other parts of the world. It is lower than the 
64.0% overall uptake reported for VACCS 1[12] 
and can be attributed to the modification in 
information transfer. In VACCS 1 the vaccine 
uptake was 51.7% for girls whose parents or 
guardians did not attend the information 
sessions and 87.5% for those whose parents or 
guardians attended. Although such information 
events result in higher uptake rates, they are 
not sustainable during a mass vaccine roll-out 
programme. Higher vaccine uptake rates can 
be accomplished by introducing an opt-out 
programme combined with assent from girls.
Several studies have confirmed the non-
inferiority of two vaccine doses compared 
with three doses.[6,7] The VCR of 95.4% 
achieved during this study compares 
favourably with other published data from 
SA[13] and with the sufficiently vaccinated 
rate (two doses 6 months apart) of 94.5% in 
Gauteng schools vaccinated in one calendar 
year during VACCS 1.[8] A vaccine programme 
in which two doses are administered should 
Table 2. Comparison of different screen uptake rates for VACCS 1 and VACCS 2
Participation rates VACCS 1, % VACCS 2, %
Return rate: Self-test kits returned used/self-test kits distributed 31.8 14.1
Participation rate: IC 15.3 16.6
Participation rate: CC 23.9 30.8
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Fig. 1. Age distribution of women participating in self-screening.
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Fig. 2. HPV self-testing screen results.
Table 3. Comparison of HPV screen outcomes for VACCS 1 and 2
HPV self-screen
VACCS 1 (Roche Linear 
Array and tampons), %
VACCS 2 (Cobas and 
Evalyn samplers), %
Invalid tests 3.6 1.3
hrHPV-negative 66.7 72.5
Any hrHPV 29.6 26.3
HPV 16- and/or 18-positive 9.1 9.4
Non-16/18 hrHPV-positive 20.6 16.9
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be less complicated to implement and more 
cost-effective, and results in the vaccination 
of more individuals.[7]
Screening for cervical cancer using conven-
tional cytology has had limited success in 
SA[1] despite being effective and having been 
available for more than 50 years. It is therefore 
vital to investigate alternative screening 
options and screening opportunities. Self-
testing for HPV as a screening tool for cervical 
cancer has been well documented and can be 
implemented even in resource-poor settings.
[14-16] Both VACCS 1 and 2 investigated the 
feasibility of implementing HPV self-screening 
in an urban population without making use of 
the health system. The method followed in the 
current study of inviting female parents and 
guardians to participate in screening and to 
distribute information about the vaccination 
of their children in an information package 
delivered at home via the children is a 
realistic, feasible and cost-effective alternative 
compared with a strategy that has not been 
widely implemented. The screened population 
falls largely into the ideal age group of women 
requiring screening (Fig. 1).
In this study, screening uptakes compared 
favourably with similar calculations from 
VACCS 1 despite the different methods of 
providing information. In VACCS 1, self-test 
kits were distributed to women after they had 
attended lectures at information events, while 
in VACCS 2 self-test kits were distributed 
to all female parents and guardians together 
with written information about cervical cancer, 
screening and vaccination. In comparable 
studies conducted on European non-respon-
ders via a mailed invitation, compliance 
rates varied between 6.4% (UK) and 31.3% 
(Netherlands), with most groups reporting 
uptake rates around 30%.[17] Screening uptakes 
achieved during this study of 30.8% (CC) 
and 29.7% (unscreened cohort) compare 
favourably with these data.
When comparing the results, it is important 
to note that the screening methodology used 
in VACCS 1 and VACCS 2 differed in two 
important aspects: (i) VACCS 1 employed 
tampon-based self-screening transported in 
a buffer solution, while Evalyn brushes were 
used for self-collection and transported dry 
in VACCS 2; and (ii) different HPV testing 
technology was used: Roche linear array in 
VACCS 1, and Roche Cobas 4800 in VACCS 2.
Conclusion
Data from the VACCS project suggest that 
school-based vaccine programmes can be 
implemented successfully in suburban areas. 
A two-dose vaccine schedule yields higher 
VCRs and will also allow for more girls to be 
vaccinated. Results from the current study 
support the SA Department of Health HPV 
vaccination programme.
Screening uptake and results in this study 
confirm the feasibility of HPV screening in this 
population. Linking self-testing HPV screening 
to HPV vaccination is a promising alternative 
to the current screening policy. The screening 
method used in this study was successful in 
reaching the appropriate target population, 
uptake rates were acceptable, and results were 
effectively communicated via the school system 
and mobile phone technology. Screening options 
other than conventional population-based 
cervical cytology are promising and should be 
further investigated and implemented.
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